Article

A Protein That Suppresses Inflammation Could Lead to New Treatments

A protein identified in a University of Central Florida lab has the power to suppress inflammation.

A protein identified in a University of Central Florida lab has the power to suppress inflammation. The discovery may help get to the root causes of disorders from arthritis to heart diseases, according to a press release.

A research team led by Pappachan Kolattukudy, director of the Burnett School of Biomedical Sciences, initially discovered MCPIP (Monocyte Chemotactic Protein-1 Induced Protein), which has now been shown to act as suppressor of inflammation. It does so by inhibiting another protein that triggers an inflammatory response in the body.

That regulatory role makes the protein an attractive target for new drug development to fight inflammatory diseases. Inflammation is an underlying problem in major chronic conditions including cardiovascular disease, arthritis, cancer, and obesity induced type 2 diabetes.

The team's findings are published in the December issue of the Journal of Experimental Medicine.

Kolattukudy and his team discovered MCPIP in 2006 while researching heart disease, but they weren't sure how it worked. The team continued to investigate the protein's nature and found one of its key jobs is to regulate inflammation.

"Identifying the important role this gene plays in the body's inflammatory response gives us another leg up in understanding the causes of debilitating diseases and, hopefully, a new path for fighting them," Kolattukudy said, in a press release.

The next step of the research will be to find drug candidates that can promote or inhibit MCPIP function for therapeutic applications.

The research team includes Kolattukudy, Jian Liang, Yasser Saad, and Jing Wang from the Burnett School of Biomedical Sciences, College of Medicine, at UCF; Quinlin Yang from the University of Alabama at Birmingham; and Dongfei Qi, Tianhua Lei and Mingui Fu from the University of Missouri, Kansas City, School of Medicine. When Fu came to UCF he joined Kolattukudy's team working on MCPIP. He continued that collaboration after he left UCF to join University of Missouri.

Source: University of Central Florida

--

What may the findings mean for future inflammation treatments? Leave a comment.

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.